Objective. This study aimed at evaluating the expression of tyrosine kinase receptors c-kit, (platelet-derived growth factor receptor-α (PDGFR-α), and PDGFR-β in ovarian granulosa cell tumors (GCTs). Study design. Primary ovarian GCT specimens were obtained for immunohistochemical staining.The expressions of c-kit, PDGFR-α, and PDGFR-β were analyzed and scored by a semiquantitative (SQ) method. Normal ovarian tissue from the same patients' specimens served as internal controls. Results. A total of 21 specimens were available for evaluation. C-kit was expressed in only 2 samples, whereas both PDGFR-α and PDGFR-β stained positive in 100% of tumors. PDGFR targets demonstrated strong positive expression in intensity and amount of tissue stained. Normal ovarian tissue demonstrated complete absence of staining for all 3 antibodies evaluated. Conclusions. The data demonstrated significant expression of PDGFR targets of imatinib mesylate in GCTs, whereas normal ovarian tissues had a complete absence of staining.This expression profile provides the rationale to investigate the role of imatinib mesylate in PDGFR-positive GCTs.
Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577-580.
2.
Tsujimura T. , Hashimoto K., Kitayama H., et al. Activating mutation in the catalytic domain of c-kit elicits hematopoietic transformation by receptor self-association not at the ligand-induced dimerization site. Blood. 1999;93:1319-1329.
3.
Morin MJFrom oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and antiangiogenic agents. Oncogene . 2000;19:6574-6583.
4.
Manning G., Whyte DB, Martinez R., Hunter T., Sudarsanam S.The protein kinase complement of the human genome. Science . 2002;298:1912-1934.
5.
Verweij J., Judson I., van Oosterom A.STI571: a magic bullet? Eur J Cancer. 2001 ;37:1816-1819.
6.
Arber DA, Tamayo R., Weiss LMParaffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum Pathol . 1998;29:498-504.
7.
Henriksen R. , Funa K., Wilander E., Bäckström T., Ridderheim M., Oberg K.Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms . Cancer Res. 1993;53:4550-4554.
8.
Matei D., Graeber TG, Baldwin RL, Karlan BY, Rao J., Chang DDGene expression in epithelial ovarian carcinoma. Oncogene . 2002;21:6289-6298.
9.
Schmandt RE, Broaddus R., Lu KH, et al. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium . Cancer. 2003;98:758-764.
10.
Versnel MA, Haarbrink M., Langerak AW, et al. Human ovarian tumors of epithelial origin express PDGF in vitro and in vivo. Cancer Genet Cytogenet. 1994;73:60-64.
11.
Wilczynski SP, Chen YY, Chen W., Howell SB, Shivley JE, Alberts DSExpression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers. Hum Pathol. 2005;36:242-249.
12.
Manne U., Myers RB, Moron C., et al. Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int J Cancer. 1997;74:346-358.
13.
Gershenson DM, Morris M., Burke TW, Lavenback C., Matthews CM, Wharton JTTreatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin . Obstet Gynecol. 1996;87:527-531.
14.
Homesley HD , Bundy BN, Hurteau JA, Roth LMBleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol. 1999;72:131-137.
15.
Lauszus FF, Petersen AC, Greisen J., Jakobsen A.Granulosa cell tumor of the ovary: a population-based study of 37 women with stage I disease. Gynecol Oncol. 2001;81:456-460.
16.
Leibl S., Bodo K., Gogg-Kammerer M., et al. Ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3, and Her-4: an immunohistochemical study. Gynecol Oncol . 2006; 101:18-23.
17.
Carvalho I. , Milanezi F., Martins A., Reis RM, Schmitt F.Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression . Breast Cancer Res. 2005;7:R788-R795.
18.
Hwang RF,Yokoi K., Bucana CD, et al. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res. 2003;9:6534-6544.
19.
Basciani S. , Brama M., Mariani S., et al. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity . Cancer Res. 2005;65:1897-1903.
20.
Beppu K., Jaboine J., Merchant MS, Mackall CL, Thiele CJEffect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst. 2004;96:46-55.
21.
Kilic T., Alberta JA, Zdunek PR, et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. 2000;60:5143-5150.
22.
Krystal GW, Honsawek S., Litz J., Buchdunger E.The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res. 2000;6:3319-3326.
23.
Merchant MS ,Woo CW, Mackall CL, Thiele CJPotential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity . J Natl Cancer Inst. 2002;94:1673-1679.
24.
Sjoblom T., Shimizu A., O'Brien KP, et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res.2001;61:5778-5783.
25.
Chu S., Alexiadis M., Fuller PJExpression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors. Gynecol Oncol. 2008;108:182-190.
26.
Tonary AM, Macdonald EA, Faught W., Senterman MK, Venderhyden BCLack of expression of c-KIT in ovarian cancers is associated with poor prognosis . Int J Cancer. 2000; 89:242-250.
27.
Inoue M., Kyo S., Fujita M., Enomoto T., Kondoh G.Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors. Cancer Res. 1994;54:3049-3053.
28.
Parrott JA, Kim G., Skinner MKExpression and action of kit ligand/stem cell factor in normal human and bovine ovarian surface epithelium and ovarian cancer. Biol Reprod . 2000;62:1600-1609.
29.
Parrott JA, Mosher R., Kim G., Skinner MKAutocrine interactions of keratinocyte growth factor, hepatocyte growth factor, and kit-ligand in the regulation of normal ovarian surface epithelial cells . Endocrinology. 2000;141:2532-2539.
